Skip to main content Skip to search Skip to main navigation

Latest News from PIC/S

From 6 to 7 November 2023, the PIC/S Committee Meeting took place in Bangkok, Thailand, chaired by Paul Gustafson from Health Canada. The Ministry of Public Health of the Thai Food and Drug Administration (Thai FDA) hosted the meeting.

The meeting was attended by 37 of the 56 Participating Authorities (PAs) as well as various applicants, pre-applicants and partner organisations.

The most important aspects in brief:

DFA submits application for pre-accession

  • The Egyptian Medicines Agency EDA applied for PIC/S pre-accession on 22 September 2023.
  • This step involves an assessment by the PIC/S to identify potential discrepancies between the PIC/S membership requirements and the applicant regulatory authority's system. The PIC/S Committee then decides on further steps, e.g. on a possible application for membership.
  • The appointment of the rapporteur, who accompanies and supervises the pre-accession process, takes place via a written procedure.

China's NMPA has applied for membership

  • On 22 September 2023, China's National Medical Products Administration (NMPA) submitted its application for the PIC/S membership, which was completed on 3 November 2023. The pre-accession procedure was initiated on 24 September 2021.
  • The regulatory authority represents all Chinese authorities that participate in the Chinese Good Manufacturing Practice Regulatory Compliance Programme (GMPRCP) of the PIC/S.
  • Jacques Morénas from the French authority ANSM has been appointed as rapporteur. He will lead the PIC/S audit team overseeing the accession process.

Memorandum of Understanding with the ICH

  • In October 2023, a Memorandum of Understanding (MoU) between the PIC/S and the International Council for Harmonisation (ICH) was signed.
  • The MoU aims to ease the cooperation on ICH guidelines of relevance to inspection activities and to provide training for assessors and inspectors.
  • As both organisations are active in the field of harmonisation of medicinal products, it is not the first rapprochement. The PIC/S holds observer status with the ICH since 2017, and many ICH regulatory members are themselves PAs with the PIC/S.

A new PIC/S chair for the period 2024-2025 was also elected at the committee meeting in early November. The committee voted unanimously for Mr Jacques Morénas.


Source:

PIC/S: Newsroom

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How is a QRM process initiated?

How is a QRM process initiated?

You can view the answer here:
Read more
FDA: Updated Pre-RFD Guidance for Combination Products

FDA: Updated Pre-RFD Guidance for Combination Products

The U.S. FDA has released an updated final guidance on preparing a Pre-Request for Designation (Pre-RFD), replacing the previous 2018 version. The revised document provides new recommendations for interacting with the Office of Combination Products (OCP) and clarifies expectations for Pre-RFD submissions.
Read more
EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

EDQM: 9 Virtual Training Modules on Ph. Eur. and CEPs

The EDQM has introduced a modular training programme covering chemically defined active substances and medicinal products. It will take place between 1 and 12 December 2025.
Read more
 Data Integrity and Data Governance

Data Integrity and Data Governance

Data integrity is a key element in the pharmaceutical quality assurance system which has gained importance in recent years, especially from the viewpoint of the authorities. In GxP-regulated companies, managers are responsible for identifying and minimising risks to data integrity (“data governance”).

Read more
EMA Clarifies “Novel or Complex Manufacturing Process” Definition

EMA Clarifies “Novel or Complex Manufacturing Process” Definition

In its Quality of Medicines Q&A – Part 1, the EMA has clarified how “novel or complex manufacturing processes” should be interpreted for variation categories Q.II.b.1 (new/replacement finished product manufacturing site) and Q.II.b.4 (change in batch size).
Read more
EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

EU: Environment Committee Comments on EU Regulation Regarding Critical Medicines

The Environment Committee of the European Parliament has issued its opinion on the proposed EU Regulation to strengthen the availability of critical medicines. Key recommendations include fast-track permitting, simplified environmental assessments, and support for strategic manufacturing projects to boost EU production capacity.
Read more
Previous
Next